Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an announcement.
Shandong Xinhua Pharmaceutical Company Limited has announced the receipt of the Drug Registration Certificate for its Alendronate Sodium Oral Solution, approved by the National Medical Products Administration. This approval allows the company to produce and sell the drug, enhancing its product portfolio and potentially strengthening its market position in the pharmaceutical industry.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production and distribution of prescription drugs. The company focuses on chemical drug production and has a significant presence in the pharmaceutical industry.
Average Trading Volume: 2,936,545
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.75B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.